SCHEMBL4363767

SCHEMBL4363767

Cc1ncoc1C(=O)Nc1cc2cc(c1)Nc1nc(ncc1Cl)Nc1cccc(c1)CC2

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 8/20 0.49
ALDH1A1 P00352 4/20 0.47
NPC1 O15118 2/20 0.47
LMNA P02545 2/20 0.47
RAB9A P51151 2/20 0.47
HSD17B10 Q99714 2/20 0.47
POLB P06746 1/20 0.47
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.45
JAK2 O60674 11/20 0.44
JAK1 P23458 11/20 0.44
JAK3 P52333 11/20 0.44
TYK2 P29597 9/20 0.44
STK4 Q13043 1/20 0.42
STK3 Q13188 1/20 0.42
STK26 Q9P289 1/20 0.42
STK24 Q9Y6E0 1/20 0.42
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4364612 0.95 ALK (0.45) ALKALDH1A1NPC1LMNARAB9A
SCHEMBL1075352 0.87 ALK (0.56) ALKALDH1A1NPC1LMNARAB9A
SCHEMBL4368492 0.85 ALK (0.55) ALKJAK2JAK1JAK3TYK2
SCHEMBL4356613 0.85 ALK (0.50) ALKALDH1A1HSD17B10SMN1; SMN2JAK2
SCHEMBL4360597 0.83 ALK (0.51) ALKJAK2JAK1JAK3TYK2
Trifluoroacetic Acid SCHEMBL4364619 0.82 ALK (0.51) ALKALDH1A1NPC1LMNARAB9A
SCHEMBL4365399 0.81 ALK (0.48) ALKJAK2JAK1JAK3TYK2
SCHEMBL1074796 0.81 ALK (0.49) ALKJAK2JAK1JAK3TYK2
SCHEMBL4354728 0.81 ALK (0.52) ALKNPC1RAB9ASMN1; SMN2JAK2
SCHEMBL4359278 0.81 ALK (0.52) ALKJAK2JAK1JAK3TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US claimed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US claimed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK ALK 3/4885ALDH1A1 2511/4885NPC1 2849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.